These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 15973626

  • 1. [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].
    Michels S, Rosenfeld PJ.
    Klin Monbl Augenheilkd; 2005 Jun; 222(6):480-4. PubMed ID: 15973626
    [Abstract] [Full Text] [Related]

  • 2. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [Abstract] [Full Text] [Related]

  • 3. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
    [Abstract] [Full Text] [Related]

  • 4. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
    Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group.
    Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antiangiogenic approaches to age-related macular degeneration today.
    Bressler NM.
    Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK.
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N.
    Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
    [Abstract] [Full Text] [Related]

  • 13. Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration.
    Mantel I, Zografos L, Ambresin A.
    Ophthalmologica; 2008 Apr; 222(5):321-3. PubMed ID: 18617755
    [Abstract] [Full Text] [Related]

  • 14. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients.
    Brown DM, Regillo CD.
    Am J Ophthalmol; 2007 Oct; 144(4):627-37. PubMed ID: 17893015
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.
    Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, Quarmby V, Lowman H, Lien S, Gaudreault J, Maia M.
    Exp Eye Res; 2007 Oct; 85(4):425-30. PubMed ID: 17714704
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ranibizumab: new drug. Macular degeneration: second-line use due to risks.
    Prescrire Int; 2008 Feb; 17(93):3-6. PubMed ID: 18354841
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.